ARIXL Stock Overview
Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Arix Bioscience plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£1.14 |
| 52 Week High | UK£1.15 |
| 52 Week Low | UK£1.06 |
| Beta | 1.01 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -45.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| ARIXL | GB Capital Markets | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.2% | 2.8% |
| 1Y | n/a | 5.8% | 1.1% |
Return vs Industry: Insufficient data to determine how ARIXL performed against the UK Capital Markets industry.
Return vs Market: Insufficient data to determine how ARIXL performed against the UK Market.
Price Volatility
| ARIXL volatility | |
|---|---|
| ARIXL Average Weekly Movement | n/a |
| Capital Markets Industry Average Movement | 4.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: ARIXL has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ARIXL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 9 | Rob Lyne | arixbioscience.com |
Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, novel therapeutics, innovative technologies, medical innovation comprising healthcare and life sciences. It seeks to invest globally.
Arix Bioscience plc Fundamentals Summary
| ARIXL fundamental statistics | |
|---|---|
| Market cap | UK£142.02m |
| Earnings (TTM) | UK£14.96m |
| Revenue (TTM) | UK£14.16m |
9.5x
P/E Ratio10.0x
P/S RatioIs ARIXL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARIXL income statement (TTM) | |
|---|---|
| Revenue | UK£14.16m |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£14.16m |
| Other Expenses | -UK£799.00k |
| Earnings | UK£14.96m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.12 |
| Gross Margin | 100.00% |
| Net Profit Margin | 105.64% |
| Debt/Equity Ratio | 0% |
How did ARIXL perform over the long term?
See historical performance and comparison